Clinical trial
A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
NCT06616584 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- May 22, 2025
- Completion date
- December 31, 2028
- Enrollment
- 378 (estimated)
- Sites
- 413
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8